In vivo recovery with products of very high purity assay discrepancies

Haemophilia

Volumn 4, Issue 4, 1998, Pages 641-645

  Lusher, J M ^a   Hillman Wiseman, C ^a   Hurst, D ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Assay discrepancies; Chromogenic assays; FVIII and FIX recovery; One stage FVIII assays

Indexed keywords

ELLAGIC ACID; KAOLIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SILICON DIOXIDE; THROMBOPLASTIN;

ADOLESCENT; ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG INFUSION; DRUG PURITY; HEALTH CARE COST; HEMOPHILIA A; HUMAN; INSTRUMENTATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; METHODOLOGY; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PRIORITY JOURNAL;

EID: 0031857499     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440641.x     Document Type: Conference Paper

References (21)

1. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost effectiveness by pharmacokinetic dosing of Factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
2. Blombäck M, Kjellman H, Allain JP, Hedner U, Schimpf K, Wiechel B. On the unreliability of one-stage factor VIII:C clotting assays after infusion of factor VIII:C concentrates. Scand J Clin Lab Invest 1987; 47: 561-6.
3. Björkman S, Carlsson M. The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia 1997; 3: 1-8.
4. Kjellman H. Calculations of factor VIII in vivo recovery and half-life. Scand J Haematol 1984; 33 (Suppl 40): 165-74.
5. Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII. Thromb Haemost 1993; 69: 87.
6. Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified factor VIII concentrates. Haemostasis 1989; 19: 131-7.
7. Mikaelsson M, Oswaldsson Y, Nilsson IM. Potency and in vivo recovery of high purity factor VIII concentrate. Thromb Haemost 1994; 72: 160-1.
8. Mikaelsson M. In the supplement issue of Haemophilia.
9. Morfini M, Longo G, Messori A, Lee M, White G, Mannucci PM, and the recombinate study group. Pharmacokinetic properties of recombinant factor VIII compare with a monoclonally purified concentrate (Hemofil M). Thromb Haemost 1992; 68: 433-5.
10. Lusher JM, Ofosu FA, Edson JR, Joist JH, Chairn SI, Weiss AE, Hillman CRL. North American study of factor VIII concentrate potency. Scand J Haematol 1984; 33 (Suppl 40): 149-60.
11. Lusher JM. Factor VIII concentrates: matching what you see with what you get (Editorial). JAMA 1985; 254: 802-3.
12. Nilsson IM, Kirkwood TBL, Barrowcliffe TW. In vivo recovery of factor VIII: a comparison of one-stage and two stage assay methods. Thromb Haemost 1979; 42: 1230-9.
13. Barrowcliffe TW. Standardization and assay. Semin Thromb Haemost 1993; 19: 73-9.
14. Langdell RD, Wagner RH, Brinkhous KM. Effect of amihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic assay procedure. J Clin Lab Med 1953; 41: 637-47.
15. Biggs R, Eveling J, Richards G. The assay of antihemophilic globulin activity. Br J Haematol 1955; 1: 20-34.
16. Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scan J Haematol 1984; 33 (Suppl 40): 139-45.
17. Allain JP, Verroust F, Soulier JP. One or two stage assays for factor VIII. Lancet 1979; 1: 1076-7.
18. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with hemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
19. Lusher JM, Wiseman C, Simpson P, Hurst P. Plasma levels measured after infusion of recombinant FVIII vary significantly with different assay methods - will the real FVIII level please stand up! Blood 1995; 86 (Suppl 1): 192a.
20. Barrowcliffe TW. Presented at the FVIII/FIX subcommittee of the Internat. Soc. Thrombosis and Haemostasis, Firenze, 1997.
21. Prowse CV. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. Thromb Haemost 1995; 74: 1191-6.